Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms

Leukemia

Volumn 29, Issue 11, 2015, Pages 2134-2142

  Molenaar, R J ^a,b   Thota, S ^a   Nagata, Y ^c   Patel, B ^a   Clemente, M ^a   Przychodzen, B ^a   Hirsh, C ^a   Viny, A D ^d   Hosano, N ^a   Bleeker, F E ^b   Meggendorfer, M ^e   Alpermann, T ^e   Shiraishi, Y ^f   Chiba, K ^f   Tanaka, H ^f   Van Noorden, C J F ^b   Radivoyevitch, T ^g   Carraway, H E ^a   Makishima, H ^a   Miyano, S ^c   Sekeres, M A ^a   Ogawa, S ^c   Haferlach, T ^e   Maciejewski, J P ^a   more..

^a TAUSSIG CANCER INSTITUTE   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c KYOTO UNIVERSITY   (Japan)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e Munich Leukaemia Laboratory   (Germany)

^f UNIVERSITY OF TOKYO   (Japan)

^g LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASXL1 PROTEIN; DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; NUCLEOPHOSMIN; PROTEIN; SRSF2 PROTEIN; STAG2 PROTEIN; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN; ONCOPROTEIN; TET2 PROTEIN, HUMAN;

ACUTE LEUKEMIA; ADULT; ADVANCED CANCER; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER THERAPY; CLONE; CROSS-SECTIONAL STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; HIGH RISK PATIENT; HUMAN; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; OVERALL SURVIVAL; PRIORITY JOURNAL; SEQUENCE ANALYSIS; ACUTE MYELOBLASTIC LEUKEMIA; AGED; ANTAGONISTS AND INHIBITORS; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; PROGNOSIS;

AGED; DNA-BINDING PROTEINS; FEMALE; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROTO-ONCOGENE PROTEINS;

EID: 84946489761     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.91     Document Type: Article

References (34)

1. Molenaar RJ, Radivoyevitch T, Maciejewski JP, van Noorden CJ, Bleeker FE. The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation. Biochim Biophys Acta Rev Cancer 2014; 1846: 326-341.
2. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058-1066.
3. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553-567.
4. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739-744.
5. Ponnaluri VK, Maciejewski JP, Mukherji M. A mechanistic overview of TETmediated 5-methylcytosine oxidation. Biochem Biophys Res Commun 2013; 436: 115-120.
6. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010; 468: 839-843.
7. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012; 483: 474-478.
8. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012; 483: 479-483.
9. Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012; 483: 484-488.
10. Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013; 339: 1621-1625.
11. Chen C, Liu Y, Lu C, Cross JR, Morris JPt, Shroff AS et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev 2013; 27: 1974-1985.
12. Kats LM, Reschke M, Taulli R, Pozdnyakova O, Burgess K, Bhargava P et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell 2014; 14: 329-341.
13. Mylonas E, Janin M, Bawa O, Opolon P, David M, Quivoron C et al. Isocitrate dehydrogenase (IDH)2 R140Q mutation induces myeloid and lymphoid neoplasms in mice. Leukemia 2014; 28: 1343-1346.
14. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013; 340: 626-630.
15. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013; 340: 622-626.
16. Davis MI, Gross S, Shen M, Straley KS, Pragani R, Lea WA et al. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1. J Biol Chem 2014; 289: 13717-13725.
17. Chaturvedi A, Araujo Cruz MM, Jyotsana N, Sharma A, Yun H, Gorlich K et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 2013; 122: 2877-2887.
18. Deng G, Shen J, Yin M, McManus J, Mathieu M, Gee P et al. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule. J Biol Chem 2014; 290: 762-774.
19. Ledford H. Metabolic quirks yield tumour hope. Nature 2014; 508: 158-159.
20. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64-69.
21. Makishima H, Yoshida K, Nguyen N, Przychodzen B, Sanada M, Okuno Y et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet 2013; 45: 942-946.
22. Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J et al. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol 2009; 27: 6109-6116.
23. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28: 241-247.
24. Stead LF, Sutton KM, Taylor GR, Quirke P, Rabbitts P. Accurately identifying lowallelic fraction variants in single samples with next-generation sequencing: applications in tumor subclone resolution. Hum Mutat 2013; 34: 1432-1438.
25. Molenaar RJ, Verbaan D, Lamba S, Zanon C, Jeuken JW, Boots-Sprenger SH et al. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol 2014; 16: 1263-1273.
26. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011; 19: 17-30.
27. Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 2011; 12: 463-469.
28. Losman JA, Kaelin WG Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 2013; 27: 836-852.
29. Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2011; 118: 3932-3941.
30. Rampal R, Alkalin A, Madzo J, Vasanthakumar A, Pronier E, Patel J et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep 2014; 9: 1841-1855.
31. Watanabe T, Nobusawa S, Kleihues P, Ohgaki HC. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009; 174: 1149-1153.
32. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2013; 343: 189-193.
33. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al. IDH1 and IDH2 Mutations in Gliomas. N Engl J Med 2009; 360: 765-773.
34. Zhou KG, Jiang LJ, Shang Z, Wang J, Huang L, Zhou JF. Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: A meta-analysis. Leuk Lymph 2012; 53: 2423-2429.